The 10-second takeaway
For the quarter ended Dec. 31 (Q3), Abaxis beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share grew significantly.
Gross margins dropped, operating margins grew, net margins grew.
Abaxis recorded revenue of $49.8 million. The eight analysts polled by S&P Capital IQ hoped for sales of $46.0 million on the same basis. GAAP reported sales were 32% higher than the prior-year quarter's $37.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.22. The eight earnings estimates compiled by S&P Capital IQ averaged $0.20 per share. GAAP EPS of $0.22 for Q3 were 69% higher than the prior-year quarter's $0.13 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 52.4%, 170 basis points worse than the prior-year quarter. Operating margin was 15.4%, 310 basis points better than the prior-year quarter. Net margin was 10.0%, 250 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $50.6 million. On the bottom line, the average EPS estimate is $0.26.
Next year's average estimate for revenue is $182.6 million. The average EPS estimate is $0.77.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 162 members out of 178 rating the stock outperform, and 16 members rating it underperform. Among 45 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 43 give Abaxis a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abaxis is outperform, with an average price target of $41.28.
Is Abaxis the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Abaxis to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.